Surgalign Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures
26 September 2022 - 10:30PM
Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical
technology company focused on elevating the standard of care by
driving the evolution of digital health, today announced the
expansion of its Fortilink product portfolio with the introduction
and commercial launch of a new family of interbody fusion devices
featuring TiPlus technology.
The new implants include Fortilink-A with TiPlus technology for
anterior lumbar interbody fusion (ALIF) procedures; Fortilink-TC
and -TS with TiPlus technology for posterior lumbar interbody
fusion (PLIF/TLIF) procedures; and Fortilink-C with TiPlus
technology for anterior cervical discectomy and fusion (ACDF)
procedures.
The new family of 3D-printed titanium (Ti) alloy interbody cages
are fully porous and designed using the benefits of 3D-printed
manufacturing without compromise of clinical requirements. With an
interconnected architecture and acid-etched nano-surface,
Fortilink-A, -TC, -TS, and -C with TiPlus technology are available
in a wide range of footprints and hyperlordotic offerings and are
designed to allow for primary stability and bony ingrowth.1
The Fortilink interbody fusion (IBF) family of implants with
TiPlus technology was designed with direct input from leading
medical practitioners with a goal to incorporate characteristics
surgeons seek in a titanium interbody fusion device. The system
features streamlined instrumentation and a wide variety of implant
sizes allowing surgeons to implant their preferred choice for the
patient.
“TiPlus is a great new offering that significantly bolsters the
interbody solutions I can offer to my patients, based on their
specific clinical need,” said Dr. Jon White, an orthopaedic spine
surgeon at Hoag Orthopedic Institute in Irvine, California. “The
acid-etched surface and optimized pore size allows for both bone
ongrowth and ingrowth, providing confidence in achieving favorable
patient outcomes.”
Dr. Aaron Creek, a spine surgeon at The Neck and Back Institute
of Florida, in Destin, added, “The expansion of the Fortilink
system to include a 3D-printed titanium implant, in addition to the
existing TETRAfuse 3D-printed polymer option, is a unique and
efficient solution. Utilizing the well-designed Fortilink
instrumentation—but with two implant offerings in different
biomaterials—allows me to better customize the treatment of my
patients.”
To learn more about the Fortilink portfolio of products sold by
Surgalign, please visit: www.surgalign.com.
About Surgalign Holdings, Inc.Surgalign
Holdings, Inc. is a global medical technology company committed to
the promise of digital health to drive transformation across the
surgical landscape. Uniquely aligned and resourced to advance the
standard of care, the company’s focus is building technologies that
physicians and other health providers will look to for what is
truly possible for their patients. Surgalign is focused on
developing solutions that predictably deliver superior clinical and
economic outcomes. Surgalign markets products throughout the United
States and in approximately 50 countries worldwide through an
expanding network of top independent distributors. Surgalign is
headquartered in Deerfield, IL, with commercial, innovation and
design centers in San Diego, CA, Warsaw and Poznan, Poland, and
Wurmlingen, Germany. Learn more at www.surgalign.com and connect on
LinkedIn and Twitter.
Forward Looking StatementThis press release
contains forward-looking statements based on management’s current
expectations, estimates and projections about our products,
company, and industry, our management's beliefs, and certain
assumptions made by our management. Words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
and other variations of such words and similar expressions are
intended to identify such forward-looking statements. These
statements are not guarantees of future performance and are subject
to risks and uncertainties, including the risks described in our
public filings with the U.S. Securities and Exchange Commission
(SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements.
Copies of the company's SEC filings may be obtained by contacting
the company or the SEC or by visiting Surgalign's website
at www.surgalign.com or the SEC's website
at www.sec.gov.
1 Data on file at Baat Medical.
|
|
|
Investor and Media Contact: |
|
Surgalign Contact: |
Glenn Wiener |
|
Kristine Simmons |
gwiener@gwcco.com |
|
ksimmons@surgalign.com |
+ 1 917 887 8434 |
|
+1 619 206 4648 |
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From Apr 2024 to May 2024
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From May 2023 to May 2024